Glooko

Last updated
Glooko, Inc
Company type Private
Industry Software
Founded2011
Headquarters Mountain View, California, U.S.
Key people
Yogen Dalal, Founder
CEO Mike Alvarez
Wende Hutton, Investor, Canaan Venture Partners
Products mHealth and Population Management for Diabetes
Website glooko.com

Glooko, Inc provides a Software-as-a-Service (SaaS) application and accompanying mobile app for diabetes patients and their healthcare providers in the United States and internationally.

Contents

An mHealth, Telemedicine and Population Management offering, Glooko is a HIPAA-compliant unified diabetes management platform that is used by both patients and their Health Care Providers (HCP). Accountable Care Organizations and Integrated Health Systems seeking to remotely monitor patient health to improve patient outcomes and reduce the costs of delivery, hospitalizations and emergency room visits have started to use telemedicine applications for patient remote monitoring to enable early warning and proactive action for issues related to chronic diseases like diabetes and hypertension.

Glooko consists of a patient mobile app, a provider population management app accessed online and a meter sync hardware device which delivers insights and population management features and enables patients to upload data from their blood glucose meters. Glooko currently supports syncing data from more than 200 blood glucose meters using a proprietary meter sync cable called the MeterSync Blue. [1] Patients can check their blood glucose meter for compatibility on the website.

Capabilities

Glooko offers a unified diabetes management platform which brings together diabetes data (blood glucose levels, diet, fitness, [2] biometrics, insulin and medication data) for patients and their healthcare providers. Patients access charts and graphs of their blood glucose levels and can maintain a digital logbook of diet, fitness, biometric, insulin and medication data via the Glooko mobile app that can be downloaded from the Apple App Store and from the Google Play App Store for iOS and Android respectively [3] . Healthcare providers access the Glooko Population Management web application to track patient and population level data. Providers can track issues over-time and are alerted to patients with issues. During the COVID-19 pandemic, Glooko offered a free tool to people with diabetes and healthcare providers to enable safe and connected patient care. [4]

History

Glooko was founded in 2011 by Internet Pioneer Yogen Dalal, Sundeep Madra, and Chamath Palihapitiya. Each founder had been impacted by diabetes in a personal way and wanted to develop an offering that could leverage the power of the Internet, mobile connectivity and big data analytics to deliver applications to improve diabetes management.

Company information

Glooko is a privately held company. Its headquarters are in Mountain View, California. As of June 2017, the company has received $71 million [5] [6] [7] in funding with the most recent round being Series C. Investors include a variety of angel investors, including Judy Estrin, The Social+Capital Partnership, Canaan Partners, Samsung and Medtronic.

See also

Related Research Articles

<span class="mw-page-title-main">Insulin pump</span> Medical device to administer insulin

An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy. The device configuration may vary depending on design. A traditional pump includes:

<span class="mw-page-title-main">Blood glucose monitoring</span> Use of a glucose monitor for testing the concentration of glucose in the blood

Blood glucose monitoring is the use of a glucose meter for testing the concentration of glucose in the blood (glycemia). Particularly important in diabetes management, a blood glucose test is typically performed by piercing the skin to draw blood, then applying the blood to a chemically active disposable 'test-strip'. The other main option is continuous glucose monitoring (CGM). Different manufacturers use different technology, but most systems measure an electrical characteristic and use this to determine the glucose level in the blood. Skin-prick methods measure capillary blood glucose, whereas CGM correlates interstitial fluid glucose level to blood glucose level. Measurements may occur after fasting or at random nonfasting intervals, each of which informs diagnosis or monitoring in different ways.

<span class="mw-page-title-main">Telehealth</span> Health care by telecommunication

Telehealth is the distribution of health-related services and information via electronic information and telecommunication technologies. It allows long-distance patient and clinician contact, care, advice, reminders, education, intervention, monitoring, and remote admissions. Telemedicine is sometimes used as a synonym, or is used in a more limited sense to describe remote clinical services, such as diagnosis and monitoring. When rural settings, lack of transport, a lack of mobility, conditions due to outbreaks, epidemics or pandemics, decreased funding, or a lack of staff restrict access to care, telehealth may bridge the gap as well as provide distance-learning; meetings, supervision, and presentations between practitioners; online information and health data management and healthcare system integration. Telehealth could include two clinicians discussing a case over video conference; a robotic surgery occurring through remote access; physical therapy done via digital monitoring instruments, live feed and application combinations; tests being forwarded between facilities for interpretation by a higher specialist; home monitoring through continuous sending of patient health data; client to practitioner online conference; or even videophone interpretation during a consult.

eHealth describes healthcare services which are supported by digital processes, communication or technology such as electronic prescribing, Telehealth, or Electronic Health Records (EHRs). The use of electronic processes in healthcare dated back to at least the 1990s. Usage of the term varies as it covers not just "Internet medicine" as it was conceived during that time, but also "virtually everything related to computers and medicine". A study in 2005 found 51 unique definitions. Some argue that it is interchangeable with health informatics with a broad definition covering electronic/digital processes in health while others use it in the narrower sense of healthcare practice using the Internet. It can also include health applications and links on mobile phones, referred to as mHealth or m-Health. Key components of eHealth include electronic health records (EHRs), telemedicine, health information exchange, mobile health applications, wearable devices, and online health information. These technologies enable healthcare providers, patients, and other stakeholders to access, manage, and exchange health information more effectively, leading to improved communication, decision-making, and overall healthcare outcomes.

<span class="mw-page-title-main">Glucose meter</span> Medical device for determining the concentration of glucose in the blood

A glucose meter, also referred to as a "glucometer", is a medical device for determining the approximate concentration of glucose in the blood. It can also be a strip of glucose paper dipped into a substance and measured to the glucose chart. It is a key element of glucose testing, including home blood glucose monitoring (HBGM) performed by people with diabetes mellitus or hypoglycemia. A small drop of blood, obtained from slightly piercing a fingertip with a lancet, is placed on a disposable test strip that the meter reads and uses to calculate the blood glucose level. The meter then displays the level in units of mg/dL or mmol/L.

The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.

<span class="mw-page-title-main">Automated insulin delivery system</span>

Automated insulin delivery systems are automated systems designed to assist people with insulin-requiring diabetes, by automatically adjusting insulin delivery in response to blood glucose levels. Currently available systems can only deliver a single hormone—insulin. Other systems currently in development aim to improve on current systems by adding one or more additional hormones that can be delivered as needed, providing something closer to the endocrine functionality of the pancreas.

<span class="mw-page-title-main">Diabetes management software</span>

Diabetes Management Software refers to software tools that run on personal computers and personal digital assistants to help persons with Type 1 and Type 2 diabetes manage the data associated with:

mHealth Medicine and public health supported by mobile devices

mHealth is an abbreviation for mobile health, a term used for the practice of medicine and public health supported by mobile devices. The term is most commonly used in reference to using mobile communication devices, such as mobile phones, tablet computers and personal digital assistants (PDAs), and wearable devices such as smart watches, for health services, information, and data collection. The mHealth field has emerged as a sub-segment of eHealth, the use of information and communication technology (ICT), such as computers, mobile phones, communications satellite, patient monitors, etc., for health services and information. mHealth applications include the use of mobile devices in collecting community and clinical health data, delivery/sharing of healthcare information for practitioners, researchers and patients, real-time monitoring of patient vital signs, the direct provision of care as well as training and collaboration of health workers.

Connected health is a socio-technical model for healthcare management and delivery by using technology to provide healthcare services remotely. Connected health, also known as technology enabled care (TEC) aims to maximize healthcare resources and provide increased, flexible opportunities for consumers to engage with clinicians and better self-manage their care. It uses readily available consumer technologies to deliver patient care outside of the hospital or doctor's office. Connected health encompasses programs in telehealth, remote care, and disease and lifestyle management. It often leverages existing technologies, such as connected devices using cellular networks, and is associated with efforts to improve chronic care. However, there is an increasing blur between software capabilities and healthcare needs whereby technologists are now providing the solutions to support consumer wellness and provide the connectivity between patient data, information and decisions. This calls for new techniques to guide Connected Health solutions such as "design thinking" to support software developers in clearly identifying healthcare requirements, and extend and enrich traditional software requirements gathering techniques.

DexCom, Inc. is a company that develops, manufactures, produces, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has manufacturing facilities in Mesa, Arizona and Batu Kawan, Malaysia.

Wireless health is the integration of wireless technology into traditional medicine, such as diagnosis, monitoring and treatment of illness, as well as other tools that can help individuals improve their personal health and wellbeing. Wireless health differs from mHealth in that wireless health solutions will not always be mobile and mobile health solutions will not always be wirelessly enabled. Mobile broadband connectivity is useful in reaching new patients in remote areas while improving productivity and convenience through data transmission.

<span class="mw-page-title-main">Remote patient monitoring</span> Technology to monitor patients outside of conventional clinical settings

Remote patient monitoring (RPM) is a technology to enable monitoring of patients outside of conventional clinical settings, such as in the home or in a remote area, which may increase access to care and decrease healthcare delivery costs. RPM involves the constant remote care of patients by their physicians, often to track physical symptoms, chronic conditions, or post-hospitalization rehab.

Telehomecare (THC) is a subfield within telehealth. It involves the delivery of healthcare services to patients at home through the use of telecommunications technologies, which enable the interaction of voice, video, and health-related data. The management of care is done from an external site by a healthcare professional.

Azumio is a mobile health company that specializes in biometric mobile technology. Founded in 2011, Azumio develops Apple iOS and Android health apps and services. Azumio has released 24 apps on iOS, 5 apps on Android, and 3 apps on Windows Phone. The company is headquartered in Palo Alto, California.

Joseph Antony Cafazzo is a Canadian biomedical engineer, educator, and researcher.

Nightscout is a free and open-source project, and associated social movement, that enables accessing and working with continuous glucose monitor (CGM) data. Nightscout software aims to give users access to their real time blood sugar data by putting this data in the cloud. In addition to browser-based data visualization, Nightscout can also be used to review data from a phone or smartwatch, or to remotely monitor CGM data for individuals with type 1 diabetes. Associated with Nightscout software is a broader "CGM in the Cloud" social movement, supporting individuals seeking to access and use realtime CGM data through commercial and DIY approaches.

<span class="mw-page-title-main">Continuous glucose monitor</span> Blood glucose monitoring device

A continuous glucose monitor (CGM) is a device used for monitoring blood glucose on a continual basis instead of monitoring glucose levels periodically by drawing a drop of blood from a finger. This is known as continuous glucose monitoring. CGMs are used by people who treat their diabetes with insulin, for example people with type 1 diabetes, type 2 diabetes, or other types of diabetes, such as gestational diabetes.

Lark Health is an American digital health company based in Mountain View, California. It provides a 24/7 nursing platform for chronic conditions, powered by artificial intelligence (AI) and has a text-messaging type interface. Lark also provides AI nurses for type 2 diabetes care, hypertension care, tobacco cessation, stress management, obesity, and more for 1.5 million patients.

References

  1. Comstock, Jonah (2014-10-02). "Glooko's new device Bluetooth-enables popular glucose meters". MobiHealthNews. Retrieved 2014-10-02.
  2. Moukheiber, Zina (2014-11-12). "How one start-up is using fitness trackers to help diabetes patients". Forbes. Retrieved 2014-11-12.
  3. Lawrence, Stacy (2014-10-02). "Glooko enables wireless smartphone access for existing blood glucose monitors". Fierce Medical Devices. Retrieved 2014-10-02.
  4. Pavlović, Ema (2020-04-29). "Technology in healthcare: how software improves medical practice?". Labs Explorer. Archived from the original on 2020-06-09. Retrieved 2020-05-05.
  5. Buhr, Sarah (2017-06-28). "Diabetes management platform Glooko raises $35 million". TechCrunch.
  6. Empson, Rip (2014-01-08). "After Arriving On Android, Glooko Lands $7M From Samsung & More To Bring Predictive Diabetes Care Global". TechCrunch. Retrieved 2014-01-08.
  7. Lomas, Natasha (2015-03-17). "Glooko Gets $16.5M Injection For Its Diabetes Management Platform". TechCrunch. Retrieved 2015-03-17.